Molecular heterogeneity in aldosterone-producing adenomas

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 3, 2016, Pages 999-1007

  Nanba, Kazutaka ^a   Chen, Andrew X ^a   Omata, Kei ^a   Vinco, Michelle ^a   Giordano, Thomas J ^a   Else, Tobias ^a   Hammer, Gary D ^a   Tomlins, Scott A ^a,b   Rainey, William E ^a  

^a Center for Organogenesis   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; DNA;

ARTICLE; ATP1A1 GENE; ATP2B3 GENE; CACNA1D GENE; CONTROLLED STUDY; DNA ISOLATION; GENE; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KCNJ5 GENE; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SOMATIC MUTATION; ADRENAL CORTEX ADENOMA; ADRENAL GLAND; ADRENALECTOMY; BIOSYNTHESIS; CHEMISTRY; DNA SEQUENCE; GENE EXPRESSION; GENETICS; HYPERALDOSTERONISM; MUTATION; PATHOLOGY;

ADRENAL GLANDS; ADRENALECTOMY; ADRENOCORTICAL ADENOMA; ALDOSTERONE; CYTOCHROME P-450 CYP11B2; DNA; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMANS; HYPERALDOSTERONISM; IMMUNOHISTOCHEMISTRY; MUTATION; SEQUENCE ANALYSIS, DNA;

EID: 84960889038     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3239     Document Type: Article

References (42)

1. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1, 125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293-2300.
2. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66:607-618.
3. Nishimoto K, Nakagawa K, Li D, et al. Adrenocortical zonation in humans under normal and pathological conditions. J Clin Endocrinol Metab. 2010;95:2296-2305.
4. Gomez-Sanchez CE, Qi X, Velarde-Miranda C, et al. Development of monoclonal antibodies against human CYP11B1 and CYP11B2. Mol Cell Endocrinol. 2014;383:111-117.
5. Nanba K, Tsuiki M, Sawai K, et al. Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry. J Clin Endocrinol Metab. 2013;98:1567-1574.
6. Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768-772.
7. Beuschlein F, Boulkroun S, Osswald A, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet. 2013;45:440-444, 444e441-e442.
8. Scholl UI, Goh G, Stolting G, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013;45:1050-1054.
9. Azizan EAB, Poulsen H, Tuluc P, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013;45:1055-1060.
10. Scholl UI, Stolting G, Nelson-Williams C, et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. eLife. 2015;4: e06315.
11. Fernandes-Rosa FL, Williams TA, Riester A, et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension. 2014;64:354-361.
12. Monticone S, Else T, Mulatero P, Williams TA, Rainey WE. Understanding primary aldosteronism: impact of next generation sequencing and expression profiling. Mol Cell Endocrinol. 2015;399: 311-320.
13. Nishimoto K, Tomlins SA, Kuick R, et al. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc Natl Acad Sci USA. 2015;112(33):E4591-E4599.
14. Pezzi V, Mathis JM, Rainey WE, Carr BR. Profiling transcript levels for steroidogenic enzymes in fetal tissues. J Steroid Biochem Mol Biol. 2003;87:181-189.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-SSC[T]) method. Methods. 2001;25:402-408.
16. Vezzosi D, Libe R, Baudry C, et al. Phosphodiesterase 11A (PDE11A) gene defects in patients with ACTH-independent ma-cronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors. J Clin Endocrinol Metab. 2012;97:E2063-E2069.
17. Rothenbuhler A, Horvath A, Libe R, et al. Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours. Clin Endocrinol (Oxf).2012; 77:195-199.
18. Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type Ia regulatory subunit in patients with the Carney complex. Nat Genet. 2000;26:89-92.
19. Beuschlein F, Fassnacht M, Assie G, et al. Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. NEngl J Med. 2014;370:1019-1028.
20. Sato Y, Maekawa S, Ishii R, et al. Recurrent somatic mutations underlie corticotropin-independent Cushing's syndrome. Science. 2014;344:917-920.
21. Horvath A, Boikos S, Giatzakis C, et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet. 2006;38:794-800.
22. Goh G, Scholl UI, Healy JM, et al. Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat Genet. 2014; 46:613-617.
23. Thiel A, Reis AC, Haase M, et al. PRKACA mutations in cortisol-producing adenomas and adrenal hyperplasia: a single-center study of 60 cases. Eur J Endocrinol. 2015;172:677-685.
24. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325:1688-1695.
25. Tissier F, Cavard C, Groussin L, et al. Mutations of β-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005;65:7622-7627.
26. Assie G, Libe R, Espiard S, et al. ARMC5 mutations in macronodu-lar adrenal hyperplasia with Cushing's syndrome. N Engl J Med. 2013;369:2105-2114.
27. Zilbermint M, Xekouki P, Faucz FR, et al. Primary aldosteronism and ARMC5 variants. J Clin Endocrinol Metab. 2015;100:E900-E909.
28. Omura M, Sasano H, Fujiwara T, Yamaguchi K, Nishikawa T. Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism. 2002;51:350-355.
29. Catterall WA. Signaling complexes of voltage-gated sodium and calcium channels. Neurosci Lett. 2010;486:107-116.
30. Azizan EA, Lam BY, Newhouse SJ, et al. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa-and zona fasciculata-like tumors. J Clin Endocrinol Metab. 2012;97: E819-E829.
31. Monticone S, Castellano I, Versace K, et al. Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Mol Cell Endocrinol. 2015;411:146-154.
32. Monticone S, Hattangady NG, Nishimoto K, et al. Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab. 2012;97:E1567-E1572.
33. Dekkers T, ter Meer M, Lenders JW, et al. Adrenal nodularity and somatic mutations inprimary aldosteronism: one node is the culprit? J Clin Endocrinol Metab. 2014;99:E1341-E1351.
34. Akerstrom T, Willenberg HS, Cupisti K, et al. Novel somatic mutations and distinct molecular signature in aldosterone-producing adenomas. Endocr Relat Cancer. 2015;22:735-744.
35. Enberg U, Volpe C, Hoog A, et al. Postoperative differentiation between unilateral adrenal adenoma and bilateral adrenal hyperplasia in primary aldosteronism by mRNA expression of the gene CYP11B2. Eur J Endocrinol. 2004;151:73-85.
36. Fallo F, Pezzi V, Barzon L, Mulatero P, Veglio F, Sonino N, Mathis JM. Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas. Eur J Endocrinol. 2002;147: 795-802.
37. Lenzini L, Seccia TM, Aldighieri E, et al. Heterogeneity of aldosterone-producing adenomas revealed by a whole transcriptome analysis. Hypertension. 2007;50:1106-1113.
38. Berthon A, Sahut-Barnola I, Lambert-Langlais S, et al. Constitutive β-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet. 2010;19:1561-1576.
39. Berthon A, Drelon C, Ragazzon B, et al. WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Hum Mol Genet. 2014;23:889-905.
40. Walczak EM, Kuick R, Finco I, et al. Wnt signaling inhibits adrenal steroidogenesis by cell-autonomous and non-cell-autonomous mechanisms. Mol Endocrinol. 2014;28:1471-1486.
41. Assie G, Letouze E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46:607-612.
42. Tadjine M, Lampron A, Ouadi L, Bourdeau I. Frequent mutations of β-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol (Oxf). 2008;68:264-270.